Abstract
A randomized, multicenter, investigator-blind trial was conducted to compare the efficacies of cefuroxime axetil and ciprofloxacin for treatment of patients with uncomplicated gonorrhea caused by penicillinase-producing Neisseria gonorrhoeae (PPNG). A total of 832 patients (434 females and 398 males) received a single oral dose of cefuroxime axetil (1,000 mg [417 patients]) or ciprofloxacin (500 mg [415 patients]). N. gonorrhoeae was eradicated from the cervix in 114 of 118 (97%) and 118 of 119 (99%) bacteriologically evaluable females treated with cefuroxime axetil and ciprofloxacin, respectively (P = 0.213; difference, -2%; 95% confidence interval, -6 to 1%), and from the urethra in 154 of 166 (93%) and 171 of 171 (100%) bacteriologically evaluable male patients treated with cefuroxime axetil and ciprofloxacin, respectively (P < 0.001; difference, -7%; 95% confidence interval, -11 to -3%). Both treatments were effective in eradicating N. gonorrhoeae in females with rectal infections (cefuroxime axetil, 29 of 30 [97%]; ciprofloxacin, 25 of 25 [100%]; P = 1.00). In small numbers of patients, cefuroxime axetil was less effective than ciprofloxacin in treating males with pharyngeal infections (eradication in 4 of 10 and in 8 of 8 patients, respectively; P = 0.013). PPNG was eradicated from the cervix in 22 of 23 (96%) and 32 of 32 (100%) bacteriologically evaluable female patients treated with cefuroxime axetil and ciprofloxacin, respectively (P = 0.418; difference, -4%; 95% confidence interval, -13 to 4%), and from the urethra in 35 of 36 (97%) and 34 of 34 (100%) bacteriologically evaluable male patients treated with cefuroxime axetil and ciprofloxacin, respectively (P = 1.00; difference, -3%; 95% confidence interval, -8 to 3%). The incidences of drug-related adverse events were similar for the two study drugs. In summary, treatment with a single oral dose of cefuroxime axetil is as effective as treatment with a single oral dose of ciprofloxacin in eradicating PPNG from males and females with uncomplicated gonorrhea (urethral and endocervical), and both regimens are well-tolerated. However, in the present study, cefuroxime axetil was less effective than ciprofloxacin in treating urethral gonococcal infections in male patients, although both study drugs were highly effective in treating cervical gonococcal infections in female patients.
Full Text
The Full Text of this article is available as a PDF (197.7 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Baddour L. M., Gibbs R. S., Mertz G., Cocchetto D. M., Noble R. C. Clinical comparison of single-oral-dose cefuroxime axetil and amoxicillin with probenecid for uncomplicated gonococcal infections in women. Antimicrob Agents Chemother. 1989 Jun;33(6):801–804. doi: 10.1128/aac.33.6.801. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fuchs P. C., Barry A. L., Baker C., Murray P. R., Washington J. A., 2nd Proposed interpretive criteria and quality control parameters for testing in vitro susceptibility of Neisseria gonorrhoeae to ciprofloxacin. J Clin Microbiol. 1991 Oct;29(10):2111–2114. doi: 10.1128/jcm.29.10.2111-2114.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gold B., Rodriguez W. J. Cefuroxime: mechanisms of action, antimicrobial activity, pharmacokinetics, clinical applications, adverse reactions and therapeutic indications. Pharmacotherapy. 1983 Mar-Apr;3(2 Pt 1):82–100. [PubMed] [Google Scholar]
- Gottlieb A., Mills J. Cefuroxime axetil for treatment of uncomplicated gonorrhea. Antimicrob Agents Chemother. 1986 Aug;30(2):333–334. doi: 10.1128/aac.30.2.333. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Handsfield H. H., McCormack W. M., Hook E. W., 3rd, Douglas J. M., Jr, Covino J. M., Verdon M. S., Reichart C. A., Ehret J. M. A comparison of single-dose cefixime with ceftriaxone as treatment for uncomplicated gonorrhea. The Gonorrhea Treatment Study Group. N Engl J Med. 1991 Nov 7;325(19):1337–1341. doi: 10.1056/NEJM199111073251903. [DOI] [PubMed] [Google Scholar]
- Knapp J. S., Ohye R., Neal S. W., Parekh M. C., Higa H., Rice R. J. Emerging in vitro resistance to quinolones in penicillinase-producing Neisseria gonorrhoeae strains in Hawaii. Antimicrob Agents Chemother. 1994 Sep;38(9):2200–2203. doi: 10.1128/aac.38.9.2200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Knapp J. S., Washington J. A., Doyle L. J., Neal S. W., Parekh M. C., Rice R. J. Persistence of Neisseria gonorrhoeae strains with decreased susceptibilities to ciprofloxacin and ofloxacin in Cleveland, Ohio, from 1992 through 1993. Antimicrob Agents Chemother. 1994 Sep;38(9):2194–2196. doi: 10.1128/aac.38.9.2194. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Moran J. S., Zenilman J. M. Therapy for gonococcal infections: options in 1989. Rev Infect Dis. 1990 Jul-Aug;12 (Suppl 6):S633–S644. doi: 10.1093/clinids/12.supplement_6.s633. [DOI] [PubMed] [Google Scholar]
- Reichman R. C., Nolte F. S., Wolinsky S. M., Greisberger C. A., Trupei M. A., Nitzkin J. Single-dose cefuroxime axetil in the treatment of uncomplicated gonorrhea: a controlled trial. Sex Transm Dis. 1985 Oct-Dec;12(4):184–187. doi: 10.1097/00007435-198510000-00003. [DOI] [PubMed] [Google Scholar]
- Smith B. R., LeFrock J. L. Cefuroxime: antimicrobial activity, Pharmacology, and clinical efficacy. Ther Drug Monit. 1983 Jun;5(2):149–160. [PubMed] [Google Scholar]
- Thornsberry C., Biddle J. W., Perine P. L., Siegel M. In vitroSusceptibility of β-Lactamase Positive and β-Lactamase Negative Strains ofNeisseria gonorrhœœto Cefuroxime. Proc R Soc Med. 1977;70(Suppl 9):122–124. doi: 10.1177/00359157770700S927. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wanas T. M., Williams P. E. Oral cefuroxime axetil compared with oral ampicillin in treating acute uncomplicated gonorrhoea. Genitourin Med. 1986 Aug;62(4):221–223. doi: 10.1136/sti.62.4.221. [DOI] [PMC free article] [PubMed] [Google Scholar]